Log in
Enquire now

List of Eiger BioPharmaceuticals patents

List of Eiger BioPharmaceuticals patents
List of CureDM patents
List of Delta Electronics patents
List of Senseeker Engineering, Inc. patents
List of companies in Nicolai Wadstrom's investment portfolio
List of portable media player products
Patents where
Current Assignee
Name
is
Eiger BioPharmaceuticalsEiger BioPharmaceuticals
Name
Description
Patent Applicant
Current Assignee
Inventor
Patent Jurisdiction
Patent Number
Date of Patent
‌
US Patent 11517532 Methods of treating hepatitis delta virus infection

Patent 11517532 was granted and assigned to Eiger BioPharmaceuticals on December, 2022 by the United States Patent and Trademark Office.

Eiger BioPharmaceuticals
Eiger BioPharmaceuticals
Eiger BioPharmaceuticals
Eiger BioPharmaceuticals
United States Patent and Trademark Office
United States Patent and Trademark Office
11517532
December 6, 2022
‌
US Patent 11571403 Methods for the treatment of non-alcoholic steatohepatitis

Patent 11571403 was granted and assigned to Eiger BioPharmaceuticals on February, 2023 by the United States Patent and Trademark Office.

Eiger BioPharmaceuticals
Eiger BioPharmaceuticals
Eiger BioPharmaceuticals
Eiger BioPharmaceuticals
United States Patent and Trademark Office
United States Patent and Trademark Office
11571403
February 7, 2023
‌
US Patent 11116820 Treatment of hyperinsulinemic hypoglycemia with exendin-4 derivatives

Patent 11116820 was granted and assigned to Eiger BioPharmaceuticals on September, 2021 by the United States Patent and Trademark Office.

Eiger BioPharmaceuticals
Eiger BioPharmaceuticals
Eiger BioPharmaceuticals
Eiger BioPharmaceuticals
United States Patent and Trademark Office
United States Patent and Trademark Office
11116820
September 14, 2021
‌
US Patent 11311519 Treatment of hepatitis delta virus infection

Patent 11311519 was granted and assigned to Eiger BioPharmaceuticals on April, 2022 by the United States Patent and Trademark Office.

Eiger BioPharmaceuticals
Eiger BioPharmaceuticals
Eiger BioPharmaceuticals
Eiger BioPharmaceuticals
United States Patent and Trademark Office
United States Patent and Trademark Office
11311519
April 26, 2022
‌
US Patent 10076512 Treatment of hepatitis delta virus infection

Patent 10076512 was granted and assigned to Eiger BioPharmaceuticals on September, 2018 by the United States Patent and Trademark Office.

Eiger BioPharmaceuticals
Eiger BioPharmaceuticals
Eiger BioPharmaceuticals
Eiger BioPharmaceuticals
United States Patent and Trademark Office
United States Patent and Trademark Office
10076512
September 18, 2018
‌
US Patent 10653753 Treatment of hyperinsulinemic hypoglycemia with exendin-4 derivatives

Patent 10653753 was granted and assigned to Eiger BioPharmaceuticals on May, 2020 by the United States Patent and Trademark Office.

Eiger BioPharmaceuticals
Eiger BioPharmaceuticals
Eiger BioPharmaceuticals
Eiger BioPharmaceuticals
United States Patent and Trademark Office
United States Patent and Trademark Office
10653753
May 19, 2020
‌
US Patent 10828283 Treatment of hepatitis delta virus infection

Patent 10828283 was granted and assigned to Eiger BioPharmaceuticals on November, 2020 by the United States Patent and Trademark Office.

Eiger BioPharmaceuticals
Eiger BioPharmaceuticals
Eiger BioPharmaceuticals
Eiger BioPharmaceuticals
United States Patent and Trademark Office
United States Patent and Trademark Office
10828283
November 10, 2020
‌
US Patent 10953072 Treatment of hepatitis delta virus infection with interferon lambda

Patent 10953072 was granted and assigned to Eiger BioPharmaceuticals on March, 2021 by the United States Patent and Trademark Office.

Eiger BioPharmaceuticals
Eiger BioPharmaceuticals
Eiger BioPharmaceuticals
Eiger BioPharmaceuticals
United States Patent and Trademark Office
United States Patent and Trademark Office
10953072
March 23, 2021
‌
US Patent 10588880 Methods and pharmaceutical compositions for the treatment of non-alcoholic steatohepatitis

Patent 10588880 was granted and assigned to Eiger BioPharmaceuticals on March, 2020 by the United States Patent and Trademark Office.

Eiger BioPharmaceuticals
Eiger BioPharmaceuticals
Eiger BioPharmaceuticals
Eiger BioPharmaceuticals
United States Patent and Trademark Office
United States Patent and Trademark Office
10588880
March 17, 2020
9 results
0 selected
9 results
0 selected
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us